Surmodics, Inc. (NASDAQ:SRDX) Shares Sold by Royce & Associates LP

Royce & Associates LP reduced its stake in shares of Surmodics, Inc. (NASDAQ:SRDX) by 36.1% during the 4th quarter, HoldingsChannel reports. The firm owned 42,305 shares of the company’s stock after selling 23,900 shares during the quarter. Royce & Associates LP’s holdings in Surmodics were worth $1,675,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Modus Advisors LLC purchased a new position in Surmodics during the fourth quarter worth approximately $40,000. Quest Partners LLC grew its holdings in Surmodics by 107,100.0% in the 3rd quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after buying an additional 1,071 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Surmodics in the 4th quarter worth $55,000. Longfellow Investment Management Co. LLC purchased a new position in shares of Surmodics during the 3rd quarter worth $67,000. Finally, SG Americas Securities LLC boosted its position in shares of Surmodics by 22.1% during the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock valued at $275,000 after acquiring an additional 1,255 shares during the last quarter. 96.63% of the stock is currently owned by institutional investors and hedge funds.

Surmodics Trading Down 0.1 %

NASDAQ SRDX opened at $29.98 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.45 and a quick ratio of 4.29. The stock has a market capitalization of $428.59 million, a P/E ratio of -29.68 and a beta of 1.19. The firm’s 50-day moving average is $33.60 and its two-hundred day moving average is $37.12. Surmodics, Inc. has a 12 month low of $25.17 and a 12 month high of $42.44.

Surmodics (NASDAQ:SRDX) last issued its quarterly earnings data on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.04. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. On average, sell-side analysts anticipate that Surmodics, Inc. will post 0.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Lake Street Capital upgraded shares of Surmodics from a “hold” rating to a “buy” rating and set a $43.00 price objective for the company in a research report on Friday, March 7th. StockNews.com assumed coverage on shares of Surmodics in a report on Monday, February 3rd. They set a “hold” rating for the company. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a report on Thursday, January 30th. Four analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, Surmodics currently has a consensus rating of “Hold” and a consensus target price of $50.00.

Surmodics Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).